Trends in prescriptions and costs of psychotropic drugs in the UK from 2013 to 2023
BJPsych Open · 2026-11 · 12 (6)
DOI: 10.1192/bjo.2026.12141 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJPsych Open, online erschienen am 30.10.2026. Verfasst von Yu-Rou Tsai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and University Hospital, Heidelberg Institute of Global Health, Heidelberg University, Germany. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Understanding prescription trends and costs of psychotropic drugs is essential to inform mental healthcare policy and practice. However, comprehensive national evidence across psychotropic drug classes is limited, and little is known on how prescription volumes changed during the COVID-19 pandemic.
Aims
We examined prescription trends and costs of psychotropic drugs in the UK and assessed changes in prescription volumes following the onset of the COVID-19 pandemic.
Method
We analysed national Prescription Cost Analysis data from 2013 to 2023, for six major psychotropic drug classes. Annual prescription volumes, total costs and average costs per drug were estimated. Linear regression was used to assess temporal trends and changes in prescription volume during the pandemic years. Costs were adjusted for inflation to 2023 prices.
Results
Between 2013 and 2023, psychotropic prescriptions grew 4% (95% CI 3.9–4.2) annually. Prescriptions for antidepressants, antipsychotics, stimulants and anti-dementia drugs increased, but not for hypnotics and anxiolytics and drugs used in substance dependence. In contrast, total costs declined by approximately £328 million, and the average cost per drug dropped from £11 to £5.9. Prescription volume remained unchanged during the pandemic years, except for anti-dementia medications, which showed an annual reduction of 17.2% (95% CI 7.8–26.6) relative to the underlying temporal trend during the study period.
Conclusions
Our observed rising prescription trend is consistent with global evidence on availability and use of psychotropic drugs. Furthermore, we found a decrease both in total drug costs and average costs per drug.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine and University Hospital, Heidelberg Institute of Global Health, Heidelberg University, Germany.
- School of Health in Social Science, The University of Edinburgh, UK.
- Institute of Social Medicine, Epidemiology and Health Economics, Charité University Hospital Berlin, Berlin, Germany.
- Department of Public Mental Health, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Germany.
- Centre for Epidemiology and Public Health, Health Service and Population Research Department, Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK.
- German Centre for Mental Health, partner site Mannheim-Heidelberg-Ulm, Berlin, Germany.
ORCID-Profile: Yu-Rou Tsai, Stefan Kohler, Ulrich Reininghaus
Zitieren
APA
Tsai, Y. R., De Allegri, M., Di Folco, S., Kohler, S., Schwannauer, M., Reininghaus, U., & Nguyen, H. T. (2026). Trends in prescriptions and costs of psychotropic drugs in the UK from 2013 to 2023. BJPsych Open, 12(6). https://doi.org/10.1192/bjo.2026.12141
Vancouver
Tsai YR, De Allegri M, Di Folco S, Kohler S, Schwannauer M, Reininghaus U, et al. Trends in prescriptions and costs of psychotropic drugs in the UK from 2013 to 2023. BJPsych Open. 2026;12(6). doi:10.1192/bjo.2026.12141
BibTeX
@article{Tsai2026,
author = {Tsai, Yu-Rou and De Allegri, Manuela and Di Folco, Simona and Kohler, Stefan and Schwannauer, Matthias and Reininghaus, Ulrich and Nguyen, Hoa Thi},
title = {Trends in prescriptions and costs of psychotropic drugs in the UK from 2013 to 2023},
journal = {BJPsych Open},
year = {2026},
volume = {12},
number = {6},
doi = {10.1192/bjo.2026.12141}
}
EUVIMED